Mandate

Vinge advises Smart Eye in a directed new share issue of MSEK 200

May 22, 2019

Vinge has advised Smart Eye AB (Nasdaq First North) on a directed new share issue that provides Smart Eye with approximately MSEK 200.

The subscription price, i.e. SEK 101.50, has been determined by an accelerated book‑building procedure corresponding to a discount of 1.6 per cent compared to the closing price on Nasdaq First North on 21 May 2019. Första AP‑fonden becomes a new major shareholder in the company after having been allotted more than half of the shares in the new issue and thereby becomes the third largest owner with 6.6 per cent of the shares and votes. In total, five major Nordic institutions were allotted approximately 75 per cent of the shares in the new share issue. The purpose of the new share issue is to finance the continued development of the business and an expanded offer towards the Chinese market. Carnegie Investment Bank has acted as sole bookrunner.

Vinge’s team has primarily consisted of responsible partner Anders Strid together with Wibeke Sorling and Edin Agic (Capital Markets), Gu Qun (China Practice), Alexander Lindeberg (IP), Victor Ericsson (Tax) as well as company assistant Camilla Andersson.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025